10-Q: Lineage Reports Q2 Loss Amid Asset Impairment

Lineage Cell Therapeutics reported a significant net loss for Q2 2025, primarily driven by a $14.8 million intangible asset impairment related to the abandoned VAC platform, despite positive clinical updates for OpRegen and OPC1.

Summary

• Net loss attributable to Lineage increased to $30.46 million for the three months ended June 30, 2025, compared to $5.76 million for the same period in 2024.
• Total revenues increased by 96% to $2.76 million for the three months ended June 30, 2025, primarily due to higher collaboration revenues from the Roche Agreement and recognition of deferred revenue from a terminated Immunomic Therapeutics, Inc. (ITI) license agreement.
• Operating expenses surged by 210% to $22.54 million for the three months ended June 30, 2025, largely due to a $14.84 million non-cash impairment charge on the VAC platform intangible asset.
• A significant non-cash loss of $12.74 million was recorded due to changes in the fair value of warrant liabilities, driven by an increase in the company's common share price.
• Cash, cash equivalents, and marketable securities stood at $42.3 million as of June 30, 2025.
• The OpRegen program, in collaboration with Roche/Genentech, presented positive 36-month visual acuity results from its Phase 1/2a clinical trial, showing durable improvements in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
• The OPC1 program initiated its DOSED clinical study, treating the first chronic spinal cord injury (SCI) patient in July 2025, marking the first inclusion of chronic injury patients in an OPC1 study.
• The VAC platform and its related research and development efforts were abandoned, resulting in the $14.8 million impairment charge and termination of the CRT License Agreement and ITI Agreement.
• An ongoing legal proceeding with Hadasit Bio-Holdings Ltd. (HBL) involves allegations that the Intercompany Agreement between Lineage and its subsidiary Cell Cure Neurosciences Ltd. (CCN) was not fairly priced, with a third-party valuation firm concluding the consideration paid by Lineage to CCN was insufficient.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a substantial increase in net loss driven by a significant intangible asset impairment and a large non-cash warrant liability adjustment. While there are positive clinical updates for lead programs (OpRegen and OPC1), the financial deterioration and the abandonment of a program, coupled with ongoing legal and geopolitical risks, outweigh the clinical progress in the short term. The company's cash position is deemed sufficient for 12 months, but future capital raises are anticipated, which could lead to further dilution.

Positives

• OpRegen (RG6501) demonstrated positive 36-month visual acuity results in its Phase 1/2a clinical trial, with gains in Best Corrected Visual Acuity (BCVA) persisting through month 36, suggesting durable effects.
• Improvement in BCVA and outer retinal structure was greater in OpRegen patients with extensive bleb coverage of their GA area, persisting through month 36.
• The OPC1 program initiated its DOSED clinical study, successfully treating the first chronic SCI patient in July 2025, expanding the patient population for future studies.
• The company has successfully produced unique cGMP banking systems for three product candidates (OpRegen, OPC1, ANP1), demonstrating reproducible and scalable cell therapy production capability.
• Collaboration revenues increased by 131% for the three months ended June 30, 2025, compared to the prior year, primarily due to progress under the Roche Agreement.

Negatives

• Net loss attributable to Lineage significantly increased to $30.46 million for the three months ended June 30, 2025, from $5.76 million in the prior year period.
• A non-cash pre-tax impairment charge of $14.84 million was recorded due to the abandonment of the VAC platform intangible asset.
• A substantial non-cash loss of $12.74 million was incurred from the change in fair value of warrant liabilities, primarily due to an increase in the company's common share price.
• Cash, cash equivalents, and restricted cash decreased by $3.58 million for the six months ended June 30, 2025.
• An ongoing legal proceeding with Hadasit Bio-Holdings Ltd. (HBL) indicates a third-party valuation firm's opinion that the consideration paid by Lineage to its subsidiary CCN under an intercompany agreement was insufficient, posing a potential financial risk.

Risks

• All manufacturing processes are conducted at the subsidiary CCN's facility in Jerusalem, Israel, making operations vulnerable to the Israeli regional conflict and broader geopolitical instability.
• Long-term closure or damage to the Israeli facility, or a significant number of employees being unable to work due to conflict, could materially and adversely impact operations.
• Commercial insurance may not cover losses from war and terrorism, and government coverage may not be maintained or sufficient.
• Macroeconomic conditions such as inflation, high interest rates, slowed economic growth, and volatility in financial markets could adversely affect business, financial condition, operating results, stock price, and ability to raise additional capital.
• Changes in the regulatory landscape, including potential reductions in funding and staffing at federal agencies like the FDA, could delay or limit the ability to obtain guidance and slow review times for product candidates.
• No assurances can be given that the company will consistently manufacture clinical quantities of product candidates in accordance with cGMP or at a cost-effective/commercially viable scale.
• The company will need significant additional capital to fund operations and continued development of product candidates, with no assurance that adequate capital will be available on favorable terms, if at all.
• The issuance of additional equity or debt securities, or the possibility thereof, may cause the common share price to decline and could result in dilution for current shareholders.
• Reliance on third-party collaborations (e.g., Roche Agreement) means milestone and royalty payments are contingent on the existence of certain intellectual property rights and subject to financial offsets.
• The outcome of the HBL legal proceeding is uncertain and could have a material adverse effect on financial position, cash flows, or operating results.

Future Outlook

Management believes current cash, cash equivalents, and marketable securities of $42.3 million are sufficient to fund planned operations through at least twelve months from the issuance date of the interim financial statements. The company expects to meet longer-term future cash requirements through current cash, anticipated milestone and other payments from collaboration agreements, and proceeds from the at-the-market offering program. Operating expenses are expected to increase as product candidates continue development and seek regulatory approval, requiring significant additional capital. Future funding may come from equity offerings, debt financings, grants, strategic alliances, or licensing agreements, with no assurance of availability on favorable terms.

Management Comments

• We believe we have reduced to practice and demonstrated a reproducible and scalable cGMP cell therapy production capability with the purity, potency, and production scale implied by an off-the-shelf allogeneic product.
• We plan to leverage this expertise to produce a cost-effective, scalable, and consistent supply of allogeneic cell transplant product candidates for ourselves and others, including for indications requiring large cell doses or large patient populations.
• We expect the cell banks we have manufactured will support a production capability exceeding the reasonably foreseeable number of patients with the conditions that OpRegen and OPC1 are currently intended to address without requiring the manufacture of a new starting master cell bank.
• We expect DOSED will enable future subsequent studies aimed to demonstrate OPC1's ability to impact functional outcomes.
• Our operations have not been materially or adversely impacted as a result of the Israeli regional conflict that began in October 2023 nor the broader regional conflict that has developed since, as of the date of this report.
• It is currently not possible to predict the scope, duration or severity of the ongoing conflict or its effects on our operations, financial condition or operating results.

Industry Context

The company operates in the clinical-stage biotechnology sector, specializing in allogeneic cell therapies for neurological and ophthalmic conditions. This sector is characterized by high research and development costs, long development timelines, and significant capital requirements. The focus on 'off-the-shelf' cell therapies addresses a key challenge in the field: scalable and cost-effective manufacturing. Positive clinical data for lead candidates like OpRegen and the advancement of OPC1 are critical for validating the platform and attracting further investment or partnerships in a competitive landscape. The abandonment of the VAC platform highlights the inherent risks and portfolio management decisions common in early-stage biotech, where programs may be discontinued if they do not meet development milestones or strategic objectives. The ongoing Israeli conflict adds a unique geopolitical risk factor for companies with significant operations in the region, potentially impacting supply chains, workforce, and overall stability.

Comparison to Industry Standards

• The positive 36-month visual acuity results for OpRegen in geographic atrophy (GA) are significant, as GA is a progressive and irreversible retinal disease with limited treatment options. Comparable companies developing GA treatments include Apellis Pharmaceuticals (SYFOVRE) and Iveric Bio (IZERVAY), which have recently received FDA approval for complement inhibitors. OpRegen's cell therapy approach aims to replace or support RPE cells, offering a different mechanism of action compared to complement inhibition, which could provide a distinct advantage if long-term structural and functional benefits are confirmed in larger trials.
• The initiation of the DOSED study for OPC1 in spinal cord injury (SCI), particularly the inclusion of chronic SCI patients, is a notable step. Many SCI cell therapy trials focus on acute or subacute injuries. Companies like StemCells Inc. (now defunct, but previously worked on neural stem cells for SCI) and Asterias Biotherapeutics (acquired by Lineage, developed OPC1) have explored similar avenues. The long-term safety profile of OPC1 (13 years for Phase 1, 7 years for Phase 1/2a) is a strong point, as long-term safety is a critical concern for cell therapies. Success in chronic SCI could open up a much larger patient population compared to acute injuries.
• The abandonment of the VAC platform and the associated $14.8 million impairment charge is a common occurrence in the biotech industry, where preclinical and early-stage programs often fail to meet efficacy or safety thresholds, or strategic fit. This is comparable to portfolio rationalization seen across the industry, where companies like Pfizer or Novartis regularly discontinue programs that do not show sufficient promise or return on investment.

Corporate Governance

Legal Proceedings

• Hadasit Bio-Holdings Ltd. (HBL) filed a motion for disclosure of documents against Cell Cure Neurosciences Ltd. (CCN) on April 17, 2023, alleging that an intercompany Collaboration and License Agreement between Lineage and CCN was not fairly priced and exploited CCN's resources for Lineage's benefit.
• A third-party valuation firm delivered a report in June 2025 stating that the consideration paid by Lineage to CCN under the Intercompany Agreement was insufficient.
• The Court has set a deadline of September 7, 2025, for the parties to advise if they have settled the matter, otherwise a hearing on HBL's motion will be held.
• The company has not recorded any accrual for a contingent liability associated with this legal proceeding, believing a liability is not probable nor estimable at this time.

Related Party Transactions

• In January 2025, Lineage sold 7,894,737 common shares and an accompanying warrant to purchase up to 7,894,737 common shares to Broadwood Partners, L.P., an affiliate of Neal Bradsher, a member of the board of directors, as part of the November 2024 Registered Direct Offering.

Stakeholder Impact

• **Shareholders:** Experience significant dilution risk from potential future equity raises and warrant exercises. The increased net loss and intangible asset impairment negatively impact shareholder equity. The ongoing legal dispute with HBL could also create uncertainty.
• **Employees:** Operations in Israel face potential disruption due to regional conflict, and some employees are subject to military call-up, which could impact workforce stability.
• **Customers/Patients:** Positive clinical trial results for OpRegen and advancement of OPC1 offer hope for future therapeutic options for ocular disorders and spinal cord injuries.
• **Creditors/Investors:** The increased net loss and reliance on future capital raises may raise concerns about financial stability, although management asserts sufficient liquidity for the next 12 months. The potential for $36 million from warrant exercise provides a potential capital inflow.

Next Steps

• Continue clinical development of OpRegen (RG6501) in the Phase 2a GAlette Study by Genentech.
• Advance the DOSED clinical study for OPC1, including continued enrollment of subacute and chronic SCI patients.
• Seek additional funding from the California Institute for Regenerative Medicine (CIRM) to support continued clinical development of OPC1.
• Monitor and address the ongoing legal proceeding with Hadasit Bio-Holdings Ltd. (HBL) regarding the Intercompany Agreement, with a court-mandated settlement discussion deadline of September 7, 2025.
• Potentially raise additional capital through equity offerings, debt financings, grants, or strategic alliances to fund future operations and product development.
• Continue to leverage expertise to produce cost-effective, scalable, and consistent supply of allogeneic cell transplant product candidates.

Key Dates

Recommendation

While the company reported a significantly increased net loss due to a large non-cash impairment charge and warrant liability adjustment, the core clinical programs, OpRegen and OPC1, showed positive progress and promising data. OpRegen's 36-month visual acuity results are encouraging for its potential in geographic atrophy, and OPC1's expansion into chronic SCI patients broadens its market opportunity. The company has sufficient cash for the next 12 months and access to additional capital through its ATM program and potential warrant exercises. However, the substantial financial losses, the abandonment of a program, and the ongoing legal dispute with HBL introduce considerable uncertainty and risk. Given the mixed signals – strong clinical progress offset by significant financial setbacks and operational risks – a 'hold' recommendation is appropriate. Investors should monitor the resolution of the legal proceeding, further clinical trial progress, and the company's ability to secure additional non-dilutive funding.

Keywords

Cell Therapy, Biotechnology, Ophthalmic Conditions, Neurological Conditions, Geographic Atrophy, Spinal Cord Injury, OpRegen, OPC1, RPE Cells, Oligodendrocyte Progenitor Cells, Clinical Trials, SEC Filing, 10-Q, Financial Results, Asset Impairment, Warrant Liability, Roche Collaboration, Genentech, Regenerative Medicine, cGMP Manufacturing, Israel Innovation Authority, Hadasit Bio-Holdings